Date: June 2023
This company is a Israel-based enterprise, pioneering the development of innovative treatments for Neuropathic Pain and other chronic diseases. Their mission is to meet the critical, unaddressed demand for non-narcotic therapeutic interventions for neuropathic pain. Their proprietary CB2 receptor agonist, identified as Drug Y, holds promising potential in this regard.
Neuropathic pain, a debilitating condition common among individuals with diabetes, cancer, neurological diseases, orthopaedic injuries, and the aging population, is inadequately addressed by current treatments that often lead to serious side effects and addiction. Drug Y is set to bring a sea change by enhancing health, quality of life, vitality, and longevity.
The market for Neuropathic Pain treatment, valued at over US$ 6,313.4 million in 2019, is expected to reach around US$ 25 billion by the end of 2027. Leveraging this opportunity, the Company’s highly skilled and experienced team is working tirelessly to navigate this evolving landscape.
Their proprietary molecule, Drug Y, triggers the body’s Endo-Cannabinoid System by latching onto the CB2 receptors, leading to the secretion of natural compounds that modulate pain and inflammation. Proven to possess anti-inflammatory and immuno-protective properties, Drug Y is a safe, non-psychoactive CB2 receptor agonist with excellent potency and high tissue penetration.
The Company has secured an exclusive licensing agreement for Drug Y's development and commercialisation. A patent, encompassing a wide array of therapeutic indications, has been registered in key markets including the USA, Europe, and the rest of the world.
To progress to key development milestones, the Company seeks an initial investment of up to $0.5 million, facilitating the commencement of regulatory compliance pre-clinical studies. An additional $2 million will be needed in subsequent fundraising to complete pre-clinical studies and prepare for FDA discussions and pre-IND meetings. The investment could be structured as a SAFE (Simple Agreement For Future Equity) agreement, though the company remains open to other investment types.
This Company presents a unique investment opportunity, promising significant market potential and crucial clinical impact.